Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis
- PMID: 32773989
- PMCID: PMC7392094
- DOI: 10.6026/97320630016301
Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis
Abstract
The new SARS-CoV-2 coronavirus is the causative agent of the COVID-19 pandemic outbreak that affected more than 190 countries worldwide with more than 292,000 confirmed cases and over 12,700 deaths. There is at the moment no vaccine or effective treatment for this disease which constitutes a serious global health problem. It is of interest to use a structure based virtual screening approach for the identification of potential inhibitors of the main protease of SARS-CoV-2 (Mpro) from antiviral drugs used to treat other viral disease such as human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections. The crystallographic structure with PDB ID: 6LU7 of Mpro in complex with the inhibitor N3 was used as a model in the virtual screening of 33 protease inhibitors collected from the ChEMBL chemical database. Molecular docking analysis was performed using the standard AutoDock vina protocol followed by ranking and selection of compounds based on their binding affinity. We report 10 candidates with optimal binding features to the active site of the protease for further consideration as potential drugs to treat patients infected with the emerging COVID-19 disease.
Keywords: COVID-19; SARS-Cov-2; inhibitors; protease; virtual screening.
© 2020 Biomedical Informatics.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7392094/bin/97320630016301F1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7392094/bin/97320630016301F2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7392094/bin/97320630016301F3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7392094/bin/97320630016301F4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7392094/bin/97320630016301F5.gif)
Similar articles
-
Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition.Med Res Rev. 2022 Mar;42(2):744-769. doi: 10.1002/med.21862. Epub 2021 Oct 26. Med Res Rev. 2022. PMID: 34697818 Free PMC article. Review.
-
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.Drug Resist Updat. 2020 Dec;53:100721. doi: 10.1016/j.drup.2020.100721. Epub 2020 Aug 26. Drug Resist Updat. 2020. PMID: 33132205 Free PMC article. Review.
-
Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.Comb Chem High Throughput Screen. 2021;24(3):441-454. doi: 10.2174/1386207323999200730205447. Comb Chem High Throughput Screen. 2021. PMID: 32748740
-
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.J Infect Public Health. 2020 Sep;13(9):1210-1223. doi: 10.1016/j.jiph.2020.06.016. Epub 2020 Jun 16. J Infect Public Health. 2020. PMID: 32561274 Free PMC article.
-
Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.J Biomol Struct Dyn. 2021 Aug;39(12):4522-4535. doi: 10.1080/07391102.2020.1779130. Epub 2020 Jun 18. J Biomol Struct Dyn. 2021. PMID: 32552534 Free PMC article.
Cited by
-
Virtual screening of substances used in the treatment of SARS-CoV-2 infection and analysis of compounds with known action on structurally similar proteins from other viruses.Biomed Pharmacother. 2022 Sep;153:113432. doi: 10.1016/j.biopha.2022.113432. Epub 2022 Jul 18. Biomed Pharmacother. 2022. PMID: 36076487 Free PMC article. Review.
-
A fuzzy logic-based computational method for the repurposing of drugs against COVID-19.Bioimpacts. 2022;12(4):315-324. doi: 10.34172/bi.2021.40. Epub 2021 Aug 10. Bioimpacts. 2022. PMID: 35975205 Free PMC article.
-
Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement.Biomed Res Int. 2022 Apr 19;2022:5904261. doi: 10.1155/2022/5904261. eCollection 2022. Biomed Res Int. 2022. PMID: 35463967 Free PMC article.
-
Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models.Curr Pharmacol Rep. 2022;8(3):212-226. doi: 10.1007/s40495-022-00285-w. Epub 2022 Apr 1. Curr Pharmacol Rep. 2022. PMID: 35381996 Free PMC article. Review.
-
In silico detection of potential inhibitors from vitamins and their derivatives compounds against SARS-CoV-2 main protease by using molecular docking, molecular dynamic simulation and ADMET profiling.J Mol Struct. 2022 Jun 15;1258:132652. doi: 10.1016/j.molstruc.2022.132652. Epub 2022 Feb 18. J Mol Struct. 2022. PMID: 35194243 Free PMC article.
References
-
- Bogoch II, et al. Journal of travel medicine. . 2020;27:1.
LinkOut - more resources
Full Text Sources
Miscellaneous